Barinthus Biotherapeutics (BRNS) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to -$0.36.
- Barinthus Biotherapeutics' EPS (Weighted Average and Diluted) fell 7142.86% to -$0.36 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.88, marking a year-over-year decrease of 2617.45%. This contributed to the annual value of -$1.55 for FY2024, which is 1859.11% up from last year.
- Per Barinthus Biotherapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.36 for Q3 2025, which was down 7142.86% from -$0.52 recorded in Q2 2025.
- In the past 5 years, Barinthus Biotherapeutics' EPS (Weighted Average and Diluted) registered a high of $0.41 during Q2 2022, and its lowest value of -$1.9 during Q1 2021.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.43 (2024), whereas its average is -$0.41.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first tumbled by 140000.0% in 2021, then skyrocketed by 26923.08% in 2022.
- Quarter analysis of 5 years shows Barinthus Biotherapeutics' EPS (Weighted Average and Diluted) stood at -$0.38 in 2021, then plummeted by 45.91% to -$0.55 in 2022, then rose by 18.84% to -$0.45 in 2023, then decreased by 16.29% to -$0.52 in 2024, then skyrocketed by 31.21% to -$0.36 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.36 in Q3 2025, compared to -$0.52 in Q2 2025 and -$0.49 in Q1 2025.